A double-blind, randomised, dose ranging, multi-centre, phase IIIb study to evaluate the efficacy and safety of high doses of candesartan cilexetil (Atacand) on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria

Trial Profile

A double-blind, randomised, dose ranging, multi-centre, phase IIIb study to evaluate the efficacy and safety of high doses of candesartan cilexetil (Atacand) on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2007

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Dec 2007 Status changed from in progress to completed.
    • 10 Jan 2007 Status change
    • 14 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top